Why the upcoming TN-401 data matters for Tenaya Therapeutics stock

Tenaya Therapeutics (TNYA) is drawing attention as investors look ahead to new clinical safety and efficacy data for TN-401, its gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, at the ASGCT 2026 meeting.

This late breaking oral presentation, together with additional abstracts on Tenaya’s gene therapy and gene editing programs, gives you fresh information to evaluate the company’s pipeline potential in the context of its early stage clinical and financial profile.

The upcoming TN-401 readout comes after a strong run, with a 22.76% 7 day share price return and 27.08% 30 day share price return, building on a 92.56% 1 year total shareholder return, despite a weak 3 year total shareholder return of 88.41% and a recent first quarter loss of US$19.27 million that was smaller than a year ago.

If you are watching gene therapy catalysts like TN-401, it can also be helpful to look at other fast growing areas of healthcare such as 35 healthcare AI stocks

With Tenaya Therapeutics trading at US$0.85 after a 93% 1 year total return and sitting about 11% below analyst targets, you have to ask whether the market is leaving meaningful upside on the table or already pricing in future growth.

Preferred Price-to-Book of 1.7x: Is it justified?

On a P/B of 1.7x at a last close of $0.85, Tenaya Therapeutics screens as cheaper than many peers, which raises the question of whether the discount reflects risk or opportunity.

The P/B ratio compares the market value of the equity to its book value, which can be useful for early stage biotechs that have limited revenue and are still loss making. For Tenaya Therapeutics, this multiple sits against a very small revenue base of $225,000 and a net loss of $83.01m, so the balance sheet and future funding needs matter more than near term earnings.

Analysts also forecast rapid revenue and earnings growth, with revenue expected to grow 64.9% per year and earnings forecast to grow 63.72% per year, even though the company is currently unprofitable and forecast to remain unprofitable in 3 years. Combined with a negative return on equity of 78.17% and shareholder dilution over the past year, the low P/B can be read as the market weighing that growth potential against funding and execution risk.

Compared to the US Biotechs industry average P/B of 2.5x and a peer group average of 16.3x, Tenaya Therapeutics trades at a steep discount on this metric. That gap suggests investors are assigning a much lower value to its asset base than to peers, despite forecasts that revenue could grow faster than both the wider US market and the Biotechs industry.

Result: Price-to-Book of 1.7x.

However, you also have to weigh clinical trial uncertainty and the company’s US$83.01m net loss, which together could quickly challenge a low P/B story.

Next Steps

Given this mix of optimism and concern, it makes sense to move fast and look at the underlying data yourself to stress test the story. To weigh both sides, start with the 1 key reward and 3 important warning signs

Looking for more investment ideas?

If you want to stay a step ahead, do not stop at a single stock. Use focused stock lists to spot clear opportunities before they feel crowded.

• Target steady compounding by reviewing 71 resilient stocks with low risk scores that aim to keep volatility in check while still giving you meaningful exposure to the market.
• Hunt for strong businesses on sale by scanning the 51 high quality undervalued stocks that combine quality metrics with pricing that may not reflect fundamentals.
• Secure potential income streams by checking out 12 dividend fortresses that offer 5%+ yields while aiming to maintain payout strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.